'Beyond Structure, Predicting Function'

SHANGHAI, Dec. 26, 2024 /PRNewswire/ -- Recently, Shanghai Matwings Technology Co., Ltd. ('Matwings'), a global leader in AI-driven protein design, announced the successful completion of Series A funding rounds, raising tens of millions of USD, led by Qiming Venture Partners.

Matwings is pioneering a new frontier in protein engineering with its proprietary AI-based general protein design platform, AccelProtein™, which directly predicts protein functionality beyond the structural data. By predicting functionality, AccelProtein™ offers a new approach for acquiring high-functioning proteins.

AccelProtein™ is built on the Pro-PRIME model, a breakthrough developed by a collaborative team led by Professor Liang Hong at Shanghai Jiao Tong University. After years of research focused on data collection, curation, and optimization, the team developed the Pro-series - an AI framework for protein design. Their work, titled "A General Temperature-Guided Language Model to Design Proteins of Enhanced Stability and Activity" was recently published in Science Advances.

A featured case of AccelProtein™'s impact is the design of a specialized Glycosyltransferase enzyme, which is used in the production of EPS-G7, a core material for pancreatitis screening. Within just 4 months, Matwings increased the enzyme's total glycosylation activity by 7 times, enhanced product specificity from 60% to 98%, and reduced hydrolytic activity by 33%. These improvements cut down the cost of EPS-G7 by 90%.

In another application, Matwings successfully engineered a super alkali-resistant affinity ligand (a nanobody) for affinity chromatography, improving alkali resistance by 3 folds, binding capacity over 100%, and heat stability by 8℃. This innovation saved millions of USD in CMC costs for a Matwings client. Additionally, scale-up production to 5000L has been successfully completed. Such advancement enables low-cost affinity chromatography purification a viable option for a wide range of biologics, bringing more cost-effective solutions for drug production.

Since 2021, Matwings has successfully delivered over 30 protein-engineering and enzyme-mining projects either proprietary (e.g., Enterokinase, Carboxypeptidase B, KEX2 Protease, Maltogenic Amylase, Subtilisin, Protein A, PETase, T7 RNA Polymerase, and phi29 DNA Polymerase) and co-developed with our stakeholders. These projects span across various applications, including drug innovation, in vitro diagnostics, nutrition and healthcare, food and beverage, and green energy.

About Matwings

Matwings, founded in 2021 by an elite team from Shanghai Jiao Tong University, is one of the earliest companies to focus on AI protein models.

Matwings is dedicated to moving beyond directed evolution methods to design and engineer functionally optimized proteins by leveraging a proprietary, pre-trained, AI-based general protein design platform with 780 million curated full-length protein sequence data, including nearly 500 million private data.

This cutting-edge technology platform, AccelProtein™, enables us to engineer proteins and uncover or de novo design novel proteins with significantly improved properties, including stability, activity, affinity, yield, etc.

To date, Matwings has successfully engineered more than 30 proteins either proprietary or co-developed with its stakeholders, and more than 40 ongoing projects across various applications in pharmaceutical industries and synthetic biology industries, e.g.  key enzymes and proteins for CMC, innovative Biologics, synthetic biology and more.

Matwings is actively seeking global partnerships to jointly develop and commercialize new products.

Contact Information:
Email: info@matwings.com
Website: https://www.matwings.com/en/ 
Tel: +86 158 2106 5410
Paper Link: https://www.science.org/doi/10.1126/sciadv.adr2641 

Source: Matwings Technology